Accurate anatomic subtyping, optimal diagnostic imaging, and molecular classification are among the most pressing needs with NETs.
The future of PRRT lies in its use in combination therapies, including PRRT with chemotherapy, immunotherapy, and as neoadjuvant/adjuvant therapy with surgery.
Targeted alpha-particle therapy is in development for targeted radionuclide therapy of NETs, employing alpha decay to treat diseased tissue at close proximity.
Telotristat ethyl is safe and effective in reducing intractable diarrhea in patients with carcinoid syndrome.
An expert working group developed specific ideas for future research programs in NETs, as well as ways to improve access to NET clinical trials.

Results 1 - 5 of 5